- Home
- SRG vs NBTX Comparison
SRG vs NBTX Comparison
Compare SRG & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRG
- NBTX
- Stock Information
- Founded
- SRG 2014
- NBTX 2003
- Country
- SRG United States
- NBTX France
- Employees
- SRG N/A
- NBTX N/A
- Industry
- SRG Real Estate Investment Trusts
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- SRG Real Estate
- NBTX Health Care
- Exchange
- SRG Nasdaq
- NBTX Nasdaq
- Market Cap
- SRG 163.3M
- NBTX 167.8M
- IPO Year
- SRG 2015
- NBTX 2020
- Fundamental
- Price
- SRG $2.83
- NBTX $4.17
- Analyst Decision
- SRG
- NBTX Strong Buy
- Analyst Count
- SRG 0
- NBTX 1
- Target Price
- SRG N/A
- NBTX $8.00
- AVG Volume (30 Days)
- SRG 127.5K
- NBTX 11.2K
- Earning Date
- SRG 05-15-2025
- NBTX 04-02-2025
- Dividend Yield
- SRG N/A
- NBTX N/A
- EPS Growth
- SRG N/A
- NBTX N/A
- EPS
- SRG N/A
- NBTX N/A
- Revenue
- SRG N/A
- NBTX N/A
- Revenue This Year
- SRG N/A
- NBTX N/A
- Revenue Next Year
- SRG N/A
- NBTX $221.06
- P/E Ratio
- SRG N/A
- NBTX N/A
- Revenue Growth
- SRG N/A
- NBTX N/A
- 52 Week Low
- SRG $2.43
- NBTX $2.76
- 52 Week High
- SRG $5.52
- NBTX $7.29
- Technical
- Relative Strength Index (RSI)
- SRG 44.87
- NBTX 66.44
- Support Level
- SRG $2.69
- NBTX $4.06
- Resistance Level
- SRG $2.91
- NBTX $4.20
- Average True Range (ATR)
- SRG 0.09
- NBTX 0.13
- MACD
- SRG -0.00
- NBTX 0.04
- Stochastic Oscillator
- SRG 46.67
- NBTX 95.64
About SRG Seritage Growth Properties
Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management, and leasing of diversified and mixed-use properties throughout the United States.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.